Stocks · News reference
Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applicationsHyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
This advancement is Hyperfine’s second FDA-cleared software package since the launch of its next-generation Swoop system in mid-2025. It builds on Hyperfine’s Optive AI software to deliver even higher image quality in
Read original at benzingaB. Riley Securities analyst Yuan Zhi reiterates Hyperfine (NASDAQ:HYPR) with a Buy and lowers the price target from $2 to $1.6.
Read original at benzingaHyperfine (NASDAQ:HYPR) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.
Read original at benzinga